| Current Price | $221.84 | Mkt Cap | $21.2B |
|---|---|---|---|
| Open | $220.60 | P/E Ratio | -11.94 |
| Prev. Close | $221.84 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $217.57 - $225.45 | Volume | 136 |
| 52-Wk Range | $124.46 - $280.62 | Avg. Daily Vol. | 192,630 |
| Current Price | $221.84 | Mkt Cap | $21.2B |
|---|---|---|---|
| Open | $220.60 | P/E Ratio | -11.94 |
| Prev. Close | $221.84 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $217.57 - $225.45 | Volume | 136 |
| 52-Wk Range | $124.46 - $280.62 | Avg. Daily Vol. | 192,630 |
The best Bull and Bear pitches based on recency and number of recommendations.
It has a strong pipeline led by two main drugs as well as the ability to use its Chinese connections to help other pharmaceutical companies in collaboration efforts.
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about BGNE.
Recs
TMFjimhalley
(< 20)
Submitted: 6/21/2021 7:42:58 PM :
Start Price:
$319.66
NASDAQ:BGNE Score:
-32.09
It has a strong pipeline led by two main drugs as well as the ability to use its Chinese connections to help other pharmaceutical companies in collaboration efforts.
Recs
CBK
(< 20)
Submitted: 7/1/2020 12:45:40 PM :
Start Price:
$191.33
NASDAQ:BGNE Score:
-21.46
-China’s biotech industry is embarking on a renaissance. BeiGene is emerging as an important leader in this movement.
-The company’s late-stage pipeline is winning commercial approvals both in China and in the rest of the developed world.
-Tislelizumab won approval in China last year and generated $20 million in product revenue during its first month of sales.
-Brukinsa was approved by the FDA.
-Amgen struck a deal with them for 20 new drugs to develop and took a 20.5% stake in them.
Recs
Bigsef77
(50.21)
Submitted: 1/15/2019 3:16:53 PM :
Start Price:
$168.98
NASDAQ:BGNE Score:
-18.07
BeiGene drug gets 'breakthrough therapy' designation from FDA
[MarketWatch]
Wallace Witkowski
,MarketWatch•January 14, 2019
U.S. shares of BeiGene Ltd. rose in the extended session Monday after the biotech drug developer said the Food and Drug Administration will expedite the regulatory process for one of its drugs. BeiGene ADRs rose 4% after hours, following a 4.6% decline to close at $137.55 Monday. The company said the FDA gave a "Breakthrough Therapy" designation to its mantle cell lymphoma treatment, meaning the experimental drug zanubrutinib will get expedited review and guidance from the agency.
Find the members with the highest scoring picks in BGNE.
portefeuille (98.44) Score: +620.47
The Score Leader is the player with the highest score across all their picks in BGNE.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| portefeuille | 98.44 |
|
|
NS | $26.13 | +748.99% | +128.52% | +620.47 | 0 Comment | |
| jeepdrew222 | 51.66 | 9/8/2016 |
|
5Y | $29.68 | +647.44% | +95.36% | +552.08 | 0 Comment | |
| portefeuille3 | 95.90 | 9/28/2016 |
|
5Y | $30.81 | +620.03% | +98.22% | +521.81 | 0 Comment | |
| SeriousK | 28.55 | 11/29/2016 |
|
5Y | $31.07 | +614.00% | +93.68% | +520.32 | 0 Comment | |
|
efarev | 35.28 | 5/23/2017 |
|
5Y | $36.87 | +501.68% | +77.99% | +423.69 | 0 Comment |
| portefeuille2 | 98.81 | 9/1/2017 |
|
5Y | $69.45 | +219.42% | +72.27% | +147.15 | 0 Comment | |
| sublimeinvestor | 27.32 | 8/8/2017 |
|
5Y | $77.30 | +186.99% | +71.98% | +115.00 | 0 Comment | |
| Plasmidologist | 27.76 | 8/8/2017 |
|
5Y | $77.49 | +186.28% | +71.96% | +114.32 | 0 Comment | |
|
|
SwampFox18 | 53.25 | 5/10/2022 |
|
5Y | $145.67 | +52.29% | +6.56% | +45.73 | 0 Comment |
| AtlanticoClub | 86.43 | 7/24/2020 |
|
5Y | $223.20 | -0.61% | +33.15% | +33.76 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
